Press "Enter" to skip to content

Rich Nations Secured Deals For Half Of COVID-19 Vaccine Supply: Report

Oxfam calculated the manufacturing capability of 5 vaccine candidates at 5.9 billion doses. (Representational)


A gaggle of rich nations representing 13 % of the worldwide inhabitants have already purchased up greater than half of the promised doses of future Covid-19 vaccines, in line with a report by Oxfam on Wednesday.

The non-governmental organisation analysed offers struck by prescription drugs and vaccine producers for the 5 main vaccine candidates at present in late-stage trials, primarily based on information collected by the analytics firm Airfinity.

“Access to a life-saving vaccine shouldn’t depend on where you live or how much money you have,” stated Robert Silverman of Oxfam America.

“The development and approval of a safe and effective vaccine is crucial, but equally important is making sure the vaccines are available and affordable to everyone. Covid-19 anywhere is Covid-19 everywhere.”

The 5 vaccines analyzed have been from AstraZeneca, Gamaleya/Sputnik, Moderna, Pfizer and Sinovac.

Oxfam calculated the mixed manufacturing capability of those 5 vaccine candidates at 5.9 billion doses, sufficient for 3 billion folks given that every one 5 future vaccines will or are extremely prone to require two doses.

Supply offers have up to now been agreed for five.three billion doses, of which 2.7 billion (51 %) have been purchased by developed nations, territories and areas, together with the US, UK, European Union, Australia, Hong Kong and Macau, Japan, Switzerland and Israel.

The remaining 2.6 billion doses have been purchased by or promised to creating nations together with India, Bangladesh, China, Brazil, Indonesia and Mexico, amongst others.

The non-profit added that one of many main candidates, developed by Moderna, has obtained $2.5 billion in dedicated taxpayers’ cash, however has stated it intends to make a revenue and has offered the choices for all its provide to wealthy nations.

Oxfam and different organizations are subsequently calling for a “people’s vaccine” freed from cost, distributed pretty primarily based on want.

“This will only be possible if pharmaceutical corporations allow vaccines to be produced as widely as possible by freely sharing their knowledge free of patents, instead of protecting their monopolies and selling to the highest bidder,” Oxfam stated.

It added that the estimated value of offering a vaccine for everybody on Earth was lower than one % of the projected value of Covid-19 to the worldwide economic system.

(Except for the headline, this story has not been edited by NDTV workers and is printed from a syndicated feed.)

Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    %d bloggers like this: